Xencor, Inc Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
Xencor, Inc (XNCR) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-02-25
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $0.00.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $0.00.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-06-30 was $0.00.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $20.40M.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Xencor, Inc equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $138.00K, a 82.75% decline from fiscal 2021.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month as first filed | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month as first filed | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month as first filed | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | -$220.00K derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$220.00K derived: sum of 3 quarters · filed 2026-02-25 | $20.40M 10-K · filed 2026-02-25 | $20.43M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | -$220.00K derived: sum of 2 quarters · filed 2025-11-05 | $20.40M 10-Q · filed 2025-11-05 | $20.43M 10-Q · filed 2024-11-06 | $20.48M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | -$220.00K 10-Q/A · filed 2025-02-24 | $20.40M 10-Q · filed 2025-08-06 | $20.43M 10-Q · filed 2024-08-05 | $20.48M derived: sum of 3 quarters · filed 2026-02-25 | $20.48M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $20.70M 10-Q · filed 2025-05-07 | $20.65M 10-Q · filed 2024-05-09 | $20.70M derived: sum of 2 quarters · filed 2026-02-25 | $20.70M derived: sum of 3 quarters · filed 2026-02-25 | $20.70M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $0.00 10-Q/A · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | $38.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $0.00 10-Q/A · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | $38.00K derived: sum of 3 quarters · filed 2025-02-27 | $38.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $0.00 10-Q/A · filed 2025-02-24 | $38.00K derived: sum of 2 quarters · filed 2025-02-27 | $38.00K derived: sum of 3 quarters · filed 2025-02-27 | $138.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $38.00K derived: sum of 2 quarters · filed 2025-02-27 | $138.00K derived: sum of 3 quarters · filed 2025-02-27 | $138.00K 10-K · filed 2025-02-27 | $100.00K 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $100.00K derived: sum of 2 quarters · filed 2023-11-08 | $100.00K 10-Q · filed 2023-11-08 | |||||
| 2022-06-30 | $100.00K 10-Q · filed 2023-08-03 | $100.00K 10-Q · filed 2023-08-03 | ||||||
| 2021-12-31 | $800.00K 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |